Manhattan Pharmaceuticals Report issue

For profit Phase 2
Founded: New York NY United States (2003)
Status: Acquired by TG Therapeutics, Inc. (2011)

Organization Overview

First Clinical Trial
2006
NCT00449202
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2007

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Manhattan Pharmaceuticals, Inc.

Active Ingredients

Drugs in Phase 2 Trials (3)

Key: Manhattan Pharmaceuticals (2) Acquired (1)

hydroxocobalamin (cyanokit) (1 trial)

oleoylestrone (2 trials)

teriparatide (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Obesity (Phase 2)

Psoriasis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 3